{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Urothelial+Cancer&page=6", "query": { "condition": "Advanced/Metastatic Urothelial Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 217, "total_pages": 22, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Urothelial+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced%2FMetastatic+Urothelial+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T06:37:51.488Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03237780", "title": "Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Recurrent Bladder Urothelial Carcinoma", "Recurrent Renal Pelvis Urothelial Carcinoma", "Recurrent Ureter Urothelial Carcinoma", "Recurrent Urethral Urothelial Carcinoma", "Stage III Bladder Cancer AJCC v8", "Stage III Renal Pelvis Cancer AJCC v8", "Stage III Ureter Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Renal Pelvis Cancer AJCC v8", "Stage IV Ureter Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Unresectable Bladder Urothelial Carcinoma", "Unresectable Renal Pelvis Urothelial Carcinoma", "Unresectable Ureter Urothelial Carcinoma", "Unresectable Urethral Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Eribulin Mesylate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2018-07-20", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Buena Park, California • Duarte, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Buena Park", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03237780" }, { "nct_id": "NCT01331824", "title": "Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Amrubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matthew Galsky", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-02", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2018-04-23", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 3, "location_summary": "Gilbert, Arizona • Indianapolis, Indiana • New York, New York", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01331824" }, { "nct_id": "NCT05176483", "title": "Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Metastatic Castration-Resistant Prostate Cancer (mCRPC)", "Urothelial Carcinoma (UC)", "Solid Tumor", "Hepatocellular Carcinoma (HCC)", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Head and Neck Squamous Cell Carcinoma (HNSCC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Non-Clear Cell Renal Cell Carcinoma (nccRCC)", "Drug-Drug Interaction (DDI)" ], "interventions": [ { "name": "Zanzalintinib", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Nivolumab + Relatlimab", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "DDI Probe Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1394, "start_date": "2021-12-14", "completion_date": "2030-06-28", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Littleton", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05176483" }, { "nct_id": "NCT07484022", "title": "Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Urothelial Cancer", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "GB-4362", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Generate Biomedicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2026-06-08", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 10, "location_summary": "Duarte, California • Irvine, California • Orlando, Florida + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tucker", "state": "Georgia" }, { "city": "Zion", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07484022" }, { "nct_id": "NCT07020117", "title": "A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma Bladder", "Triple Negative Breast Cancer (TNBC)", "Hormone Receptor Positive Breast Adenocarcinoma", "Non Small Cell Lung Cancer", "Cervical Adenocarcinoma", "Colorectal Adenocarcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "[225Ac]Ac-AKY-1189 (therapeutic)", "type": "DRUG" }, { "name": "[64Cu]Cu-AKY-1189 (imaging)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aktis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-08-22", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Miami, Florida + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07020117" }, { "nct_id": "NCT03682068", "title": "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable Locally Advanced Urothelial Cancer", "Metastatic Urothelial Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Cisplatin + Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin + Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1246, "start_date": "2018-09-27", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Bakersfield, California • Fullerton, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03682068" }, { "nct_id": "NCT05867121", "title": "A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Gastric Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "RO7496353", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "S-1", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 102, "start_date": "2023-10-02", "completion_date": "2026-03-16", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 3, "location_summary": "Los Angeles, California • New Haven, Connecticut • Philadelphia, Pennsylvania", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05867121" }, { "nct_id": "NCT00714948", "title": "Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "URINARY BLADDER" ], "interventions": [ { "name": "gemcitabine and cisplatin plus sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2008-07", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2015-11-16", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00714948" }, { "nct_id": "NCT03628716", "title": "CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "CV301", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2018-09-18", "completion_date": "2021-02-02", "has_results": true, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 6, "location_summary": "Tampa, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03628716" }, { "nct_id": "NCT02735252", "title": "PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostate Cancer", "Advanced Renal Cell Carcinoma", "Advanced Urothelial Carcinoma", "Genitourinary Cancer" ], "interventions": [ { "name": "Systemic therapy", "type": "OTHER" }, { "name": "StrataNGS", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 156, "start_date": "2016-05-25", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-21T06:37:51.488Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02735252" } ] }